Cargando…

Infiltration of T Cells and Programmed Cell Death Ligand 1-expressing Macrophages as a Potential Predictor of Lenvatinib Response in Hepatocellular Carcinoma

BACKGROUND/AIMS: Lenvatinib was recently proven to be non-inferior to sorafenib in treating unresectable hepatocellular carcinoma (HCC) in a phase-3 randomized controlled trial. In this study, we investigated whether the response to lenvatinib was affected by tumor immunogenicity. METHODS: Between M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sung, Pil Soo, Cho, Sung Woo, Lee, Jaejun, Yang, Hyun, Jang, Jeong Won, Bae, Si Hyun, Choi, Jong Young, Yoon, Seung Kew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Liver Cancer Association 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035673/ https://www.ncbi.nlm.nih.gov/pubmed/37384325 http://dx.doi.org/10.17998/jlc.20.2.128

Ejemplares similares

Comparative Analysis of Lenvatinib and Hepatic Arterial Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multi-Center, Propensity Score Study
por: Lee, Jaejun, et al.
Publicado: (2021)

Higher Number of Tumor-Infiltrating PD-L1+ Cells Is Related to Better Response to Multikinase Inhibitors in Hepatocellular Carcinoma
por: Han, Ji Won, et al.
Publicado: (2023)

Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma
por: Park, Dong-Jun, et al.
Publicado: (2021)

A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC
por: Lee, Jaejun, et al.
Publicado: (2020)

Effects of Positive Hepatitis B Core Antibody and Metabolic Disorders in Hepatocellular Carcinoma in an Endemic Area of Hepatitis B Virus
por: Lee, Hae Lim, et al.
Publicado: (2021)

Real-World Outcomes of Nivolumab in Patients With Unresectable Hepatocellular Carcinoma in an Endemic Area of Hepatitis B Virus Infection
por: Sung, Pil Soo, et al.
Publicado: (2020)

MiR-23b-3p suppresses epithelial-mesenchymal transition, migration, and invasion of hepatocellular carcinoma cells by targeting c-MET
por: Park, Na Ri, et al.
Publicado: (2022)

Diffusion-Weighted Magnetic Resonance Imaging in Hepatocellular Carcinoma as a Predictor of a Response to Cisplatin-Based Hepatic Arterial Infusion Chemotherapy
por: Sung, Pil Soo, et al.
Publicado: (2020)

Lenvatinib Induces Immunogenic Cell Death and Triggers Toll-Like Receptor-3/4 Ligands in Hepatocellular Carcinoma
por: Zhou, Cheng, et al.
Publicado: (2023)

Successful Sequential Therapy Involving Regorafenib after Failure of Sorafenib in a Patient with Recurrent Hepatocellular Carcinoma after Liver Transplantation
por: Lee, Soon Kyu, et al.
Publicado: (2020)

Upregulation of programmed death ligand-1 in tumor-associated macrophages affects chemotherapeutic response in ovarian cancer cells
por: Jang, Yong Soo, et al.
Publicado: (2023)

Clinical characteristics of portal hypertension complicated by gastroesophageal varices in patients with my- eloproliferative neoplasms
por: Lee, Jaejun, et al.
Publicado: (2020)

Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma
por: Lee, Soon Kyu, et al.
Publicado: (2021)

Expert consensus on the management of adverse events in patients receiving lenvatinib for hepatocellular carcinoma
por: Kim, Bo Hyun, et al.
Publicado: (2021)

Application of Helical Tomotherapy for Two Cases of Advanced Hepatocellular Carcinoma
por: Kim, Joon Sung, et al.
Publicado: (2011)

Expression of Programmed Death Receptor Ligand 1 with High Tumor-Infiltrating Lymphocytes Is Associated with Better Prognosis in Breast Cancer
por: Bae, Sang Byung, et al.
Publicado: (2016)

Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma
por: Sung, Pil Soo
Publicado: (2022)

Exosomal miR-125b Exerts Anti-Metastatic Properties and Predicts Early Metastasis of Hepatocellular Carcinoma
por: Kim, Hye Seon, et al.
Publicado: (2021)

Diagnostic performance of serum exosomal miRNA-720 in hepatocellular carcinoma
por: Jang, Jeong Won, et al.
Publicado: (2022)

Anti-fibrotic effects of branched-chain amino acids on hepatic stellate cells
por: Lee, Hae Lim, et al.
Publicado: (2022)

EpCAM-high liver cancer stem cells resist natural killer cell–mediated cytotoxicity by upregulating CEACAM1
por: Park, Dong Jun, et al.
Publicado: (2020)

Persistence of intrahepatic hepatitis B virus DNA integration in patients developing hepatocellular carcinoma after hepatitis B surface antigen seroclearance
por: Jang, Jeong Won, et al.
Publicado: (2021)

Reactivation of Hepatitis B Virus in HBsAg-Negative Patients with Hepatocellular Carcinoma
por: Jang, Jeong Won, et al.
Publicado: (2015)

Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis
por: Lee, Sung Won, et al.
Publicado: (2020)

Circulating pro- and anti-angiogenic factors in multi-stage liver disease and hepatocellular carcinoma progression
por: Joo, Yu Young, et al.
Publicado: (2019)

Intrahepatic infiltration of activated CD8(+) T cells and mononuclear phagocyte is associated with idiosyncratic drug-induced liver injury
por: Yang, Hyun, et al.
Publicado: (2023)

Whole blood viscosity is associated with extrahepatic metastases and survival in patients with hepatocellular carcinoma
por: Han, Ji Won, et al.
Publicado: (2021)

Rapidly Progressing Budd-Chiari Syndrome Complicated by Hepatocellular Carcinoma
por: Jang, Jeong Won, et al.
Publicado: (2003)

Long-Term Survival in a Patient With Ruptured Hepatocellular Carcinoma
por: Kim, Joon Sung, et al.
Publicado: (2009)

Early Predictors of Objective Response in Patients with Hepatocellular Carcinoma Undergoing Lenvatinib Treatment
por: Saeki, Issei, et al.
Publicado: (2020)

Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma
por: Song, Myeong Jun, et al.
Publicado: (2016)

Hemorheological Alteration in Patients Clinically Diagnosed with Chronic Liver Diseases
por: Jang, Bohyun, et al.
Publicado: (2016)

Significance of TERT Genetic Alterations and Telomere Length in Hepatocellular Carcinoma
por: Jang, Jeong-Won, et al.
Publicado: (2021)

Corrigendum: Intrahepatic infiltration of activated CD8(+) T cells and mononuclear phagocyte is associated with idiosyncratic drug-induced liver injury
por: Yang, Hyun, et al.
Publicado: (2023)

Intrahepatic inflammatory IgA(+)PD-L1(high) monocytes in hepatocellular carcinoma development and immunotherapy
por: Sung, Pil Soo, et al.
Publicado: (2022)

Clinicopathologic significance of the expression of Snail in hepatocellular carcinoma
por: Woo, Hyun Young, et al.
Publicado: (2011)

Multidisciplinary treatment with immune checkpoint inhibitors for advanced stage hepatocellular carcinoma
por: Lee, Ahlim, et al.
Publicado: (2022)

Chelidonine enhances the antitumor effect of lenvatinib on hepatocellular carcinoma cells
por: Hou, Fang-jie, et al.
Publicado: (2019)

Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells
por: Shi, Tingting, et al.
Publicado: (2021)

EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells
por: He, Xiaoping, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p22e18bfmkmhu2stdb7p0ug10h